1. Home
  2. TTEC vs ZNTL Comparison

TTEC vs ZNTL Comparison

Compare TTEC & ZNTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TTEC Holdings Inc.

TTEC

TTEC Holdings Inc.

HOLD

Current Price

$3.57

Market Cap

187.4M

Sector

Technology

ML Signal

HOLD

Logo Zentalis Pharmaceuticals Inc.

ZNTL

Zentalis Pharmaceuticals Inc.

HOLD

Current Price

$1.36

Market Cap

118.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TTEC
ZNTL
Founded
1982
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
187.4M
118.3M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
TTEC
ZNTL
Price
$3.57
$1.36
Analyst Decision
Hold
Buy
Analyst Count
3
6
Target Price
$3.50
$5.87
AVG Volume (30 Days)
321.9K
766.1K
Earning Date
11-06-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,134,379,000.00
$26,865,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.49
$1.01
52 Week High
$5.60
$3.33

Technical Indicators

Market Signals
Indicator
TTEC
ZNTL
Relative Strength Index (RSI) 51.37 45.25
Support Level $3.44 $1.33
Resistance Level $3.72 $1.46
Average True Range (ATR) 0.17 0.07
MACD -0.03 -0.00
Stochastic Oscillator 22.02 21.87

Price Performance

Historical Comparison
TTEC
ZNTL

About TTEC TTEC Holdings Inc.

TTEC Holdings Inc provides customer engagement management tools and services. The company operates through four operating segments that are organized into two groups, TTEC Digital and TTEC Engage. TTEC Digital is engaged in building and implementing cloud-based and on-premises customer experience tools that enable clients to develop customer engagement strategies. TTEC Engage focuses on delivering sales and marketing solutions to help clients boost their revenue as well as on managing customer's front-to-back office processes to optimize the customer experience. TTEC Engage contributes the vast majority of the company's revenue, and its sales are derived from the United States and Canada, followed by Philippines, Asia-Pacific and India.

About ZNTL Zentalis Pharmaceuticals Inc.

Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Share on Social Networks: